Scientists hunt for immune clues in rare salivary gland cancers
NCT ID NCT06047236
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for 300 people with salivary gland tumors (both cancerous and non-cancerous) to learn how the immune system reacts to these rare cancers. Researchers will collect tumor tissue and blood samples before and after treatment to find immune markers that might predict how the disease will progress. The goal is to better understand the disease and pave the way for future immunotherapy treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BENIGN SALIVARY GLAND TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Universitätsklinikum Erlangen, HNO
RECRUITINGErlangen, Bavaria, 91054, Germany
-
Universitätsklinikum Erlangen, Strahlenklinik
RECRUITINGErlangen, Bavaria, 91054, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- New PET tracer could spot cancers that standard scans overlook
- Drug duo takes on rare head and neck tumors
- New pill-chemo combo takes on hard-to-treat cancers
- AI analyzes 10,000 patient records to predict head and neck cancer recurrence
- Common pain gel could shield cancer patients from radiation burns